These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30347325)

  • 1. Determinants of high availability of methamphetamine, cannabis, LSD and ecstasy in New Zealand: Are drug dealers promoting methamphetamine rather than cannabis?
    Wilkins C; Romeo JS; Rychert M; Prasad J; Graydon-Guy T
    Int J Drug Policy; 2018 Nov; 61():15-22. PubMed ID: 30347325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of using social media to purchase drugs in New Zealand: Findings from a large-scale online survey.
    van der Sanden R; Wilkins C; Romeo JS; Rychert M; Barratt MJ
    Int J Drug Policy; 2021 Dec; 98():103430. PubMed ID: 34487954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of the retail price of illegal drugs in New Zealand.
    Wilkins C; Romeo JS; Rychert M; Prasad J; Graydon-Guy T
    Int J Drug Policy; 2020 Apr; 79():102728. PubMed ID: 32283351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Trends in Alcohol and Other Drug Use Among Police Detainees in New Zealand, 2010-2015.
    Wilkins C; Prasad J; Parker K; Rychert M; Barnes HM
    Curr Top Behav Neurosci; 2017; 34():161-172. PubMed ID: 28434182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathways into ecstasy use: the role of prior cannabis use and ecstasy availability.
    Zimmermann P; Wittchen HU; Waszak F; Nocon A; Höfler M; Lieb R
    Drug Alcohol Depend; 2005 Sep; 79(3):331-41. PubMed ID: 15913921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths.
    Wu LT; Schlenger WE; Galvin DM
    Drug Alcohol Depend; 2006 Sep; 84(1):102-13. PubMed ID: 16483730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabis 'tinny' houses in New Zealand: implications for the use and sale of cannabis and other illicit drugs in New Zealand.
    Wilkins C; Reilly JL; Casswell S
    Addiction; 2005 Jul; 100(7):971-80. PubMed ID: 15955013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Driving under the influence among frequent ecstasy consumers in Australia: trends over time and the role of risk perceptions.
    Matthews AJ; Bruno R; Dietze P; Butler K; Burns L
    Drug Alcohol Depend; 2014 Nov; 144():218-24. PubMed ID: 25282306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Illicit drug use among New Zealand gay and bisexual men: Prevalence and association with sexual health behaviours.
    Saxton P; Newcombe D; Ahmed A; Dickson N; Hughes A
    Drug Alcohol Rev; 2018 Feb; 37(2):180-187. PubMed ID: 28439922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ecstasy and new patterns of drug use: a normal population study.
    Pedersen W; Skrondal A
    Addiction; 1999 Nov; 94(11):1695-706. PubMed ID: 10892008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do police arrestees substitute legal highs for other drugs?
    Wilkins C; Parker K; Prasad J; Jawalkar S
    Int J Drug Policy; 2016 May; 31():74-9. PubMed ID: 26948501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of comorbid cannabis and methamphetamine use on mental health among regular ecstasy users.
    Scott LA; Roxburgh A; Bruno R; Matthews A; Burns L
    Addict Behav; 2012 Sep; 37(9):1058-62. PubMed ID: 22607716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent trends in pharmaceutical drug use among frequent injecting drug users, frequent methamphetamine users and frequent ecstasy users in New Zealand, 2006-2009.
    Wilkins C; Sweetsur P; Griffiths R
    Drug Alcohol Rev; 2011 May; 30(3):255-63. PubMed ID: 21545555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Instability of the ecstasy market and a new kid on the block: mephedrone.
    Brunt TM; Poortman A; Niesink RJ; van den Brink W
    J Psychopharmacol; 2011 Nov; 25(11):1543-7. PubMed ID: 20826554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Club drug use among youths in treatment for substance abuse.
    Hopfer C; Mendelson B; Van Leeuwen JM; Kelly S; Hooks S
    Am J Addict; 2006; 15(1):94-9. PubMed ID: 16449098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Salvia divinorum--representation of a new drug in the Internet].
    Siemann H; Specka M; Schifano F; Deluca P; Scherbaum N
    Gesundheitswesen; 2006 May; 68(5):323-7. PubMed ID: 16773554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with driving under the influence of alcohol and drugs among an Australian sample of regular ecstasy users.
    Matthews A; Bruno R; Johnston J; Black E; Degenhardt L; Dunn M
    Drug Alcohol Depend; 2009 Feb; 100(1-2):24-31. PubMed ID: 19013726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rave drugs: pharmacological considerations.
    Klein M; Kramer F
    AANA J; 2004 Feb; 72(1):61-7. PubMed ID: 15098519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National population size estimation of illicit drug users through the network scale-up method in 2013 in Iran.
    Nikfarjam A; Shokoohi M; Shahesmaeili A; Haghdoost AA; Baneshi MR; Haji-Maghsoudi S; Rastegari A; Nasehi AA; Memaryan N; Tarjoman T
    Int J Drug Policy; 2016 May; 31():147-52. PubMed ID: 26980349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual dollar expenditure and earnings from cannabis in the New Zealand population.
    Wilkins C; Sweetsur P
    Int J Drug Policy; 2007 May; 18(3):187-93. PubMed ID: 17689365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.